Inovio Pharmaceuticals (INO) Net Margin (2010 - 2025)

Inovio Pharmaceuticals (INO) posted Net Margin of 58023.74% for Q1 2025, down 247.82% sequentially from 16681.89% in Q4 2024.

Inovio Pharmaceuticals (INO) Net Margin (2010 - 2025) Analysis & Trends

Inovio Pharmaceuticals has reported Net Margin for 16 years, with the latest figure at 58023.74% in Q1 2025.

Quarterly Net Margin changed N/A year-over-year to 58023.74% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 151026.13% (down 10003684.0% YoY) and the FY2025 annual result came in at 708381.84%, down 49858007.0% from the prior year.
Net Margin slipped to 58023.74% in Q1 2025 per INO's latest filing, from 16681.89% in the prior quarter.
Over five years, Net Margin peaked at 412.75% in Q3 2022 and troughed at 58023.74% in Q1 2025.
A 5-year average of 24428.94% and a median of 20627.17% in 2021 frame the typical range for Net Margin.
The widest YoY moves for Net Margin: up 2021442 bps in 2022, down 3094196 bps in 2022.
Over 5 years, Net Margin stood at 12745.28% in 2021, then sank by 243 bps to 43687.24% in 2022, then surged by 44 bps to 24357.91% in 2023, then jumped by 32 bps to 16681.89% in 2024, then tumbled by 248 bps to 58023.74% in 2025.
According to Business Quant data, Net Margin over the past three periods registered 58023.74%, 16681.89%, and 32959.09% for Q1 2025, Q4 2024, and Q2 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Inovio Pharmaceuticals	97.94 Mn	97.94 Mn	-	-

Download Data